The Potential of Mur Enzymes as Targets for Antimicrobial Drug Discovery
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The extensive development in the strains of resistant bacteria is a potential hazard to public health worldwide. This necessitates the development of newer agents with the antibacterial property having new mechanisms of action. Mur enzymes catalyze the steps related to the biosynthesis of peptidoglycan, which constitutes a major part of the cell wall in bacteria. Peptidoglycan increases the stiffness of the cell wall, helping it to survive in unfavorable conditions. Therefore, the inhibition of Mur enzymes may lead to novel antibacterial agents that may help in controlling or overcoming bacterial resistance. Mur enzymes are classified into MurA, MurB, MurC, MurD, MurE, and MurF. Until-date, multiple inhibitors are reported for each class of the Mur enzymes. In this review, we have summarized the development of Mur enzyme inhibitors as antibacterial agents in the last few decades.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current drug targets - 24(2023), 8 vom: 08., Seite 627-647 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Dharmendra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 29.08.2023 Date Revised 02.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389450124666230608150759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357935616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357935616 | ||
| 003 | DE-627 | ||
| 005 | 20231226073653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450124666230608150759 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM357935616 | ||
| 035 | |a (NLM)37291783 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Dharmendra |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Potential of Mur Enzymes as Targets for Antimicrobial Drug Discovery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2023 | ||
| 500 | |a Date Revised 02.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The extensive development in the strains of resistant bacteria is a potential hazard to public health worldwide. This necessitates the development of newer agents with the antibacterial property having new mechanisms of action. Mur enzymes catalyze the steps related to the biosynthesis of peptidoglycan, which constitutes a major part of the cell wall in bacteria. Peptidoglycan increases the stiffness of the cell wall, helping it to survive in unfavorable conditions. Therefore, the inhibition of Mur enzymes may lead to novel antibacterial agents that may help in controlling or overcoming bacterial resistance. Mur enzymes are classified into MurA, MurB, MurC, MurD, MurE, and MurF. Until-date, multiple inhibitors are reported for each class of the Mur enzymes. In this review, we have summarized the development of Mur enzyme inhibitors as antibacterial agents in the last few decades | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antibacterial agents | |
| 650 | 4 | |a antimicrobial | |
| 650 | 4 | |a inhibitor | |
| 650 | 4 | |a ligase | |
| 650 | 4 | |a mur enzymes | |
| 650 | 4 | |a peptidoglycan | |
| 650 | 7 | |a Peptidoglycan |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Sarkar, Nandan |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Kuldeep K |e verfasserin |4 aut | |
| 700 | 1 | |a Bisht, Dheeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Mandal, Bitasta |e verfasserin |4 aut | |
| 700 | 1 | |a Rajagopal, Mogana |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Yadu Nandan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d 2000 |g 24(2023), 8 vom: 08., Seite 627-647 |w (DE-627)NLM113669291 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:8 |g day:08 |g pages:627-647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389450124666230608150759 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 8 |b 08 |h 627-647 | ||